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Abstract 
Objectives: Apathy is common, impactful, and difficult to manage in people with dementia. 
We evaluated the efficacy of non-pharmacological interventions, exercise and social 
interaction, in combination with antipsychotic review, to reduce apathy in people with 
dementia living in nursing homes in a cluster randomised controlled trial (RCT). 
Methods: Well-being and health for people with dementia (WHELD) programme included a 
2X2X2 factorial cluster RCT involving people with dementia living in 16 nursing homes in 
UK. All homes received training in person-centred care, and were randomised to receive 
antipsychotic review, social interaction, and exercise, either alone or in combinations. Apathy 
was one of the secondary outcomes of the WHELD trial, and it was measured by the 
Neuropsychiatric Inventory-nursing home version at baseline and nine months (N=273). We 
employed multilevel mixed effects linear regression models to assess the impact of the 
interventions on apathy.  
Results: Prevalence of apathy was 44.0% (n=120; 95% CI 38.1-49.9%) at baseline. Severity 
of apathy had significant positive correlations with dementia severity, neuropsychiatric 
symptoms, depressive symptoms, agitation, and the needs of the people with dementia 
(p<0.001). Antipsychotic review reduced antipsychotic use, but it significantly increased 
apathy (β=5.37; SE=0.91; p<0.001). However, antipsychotic review in combination with 
either social interaction (β=-5.84; SE=1.15; p<0.001) or exercise (β=-7.54; SE=0.93; 
p<0.001) significantly reduced apathy.  
Conclusions: Antipsychotic review can play a significant role in improving apathy in people 
with dementia living in nursing homes, when combined with psychosocial interventions such 
as social interaction and exercise. Guidance must be adapted to reflect this subtlety in care. 
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Introduction  
 Dementia affects 35 million people around the world. As the condition 
progresses many individuals move to reside in long-term care facilities. In the UK, these 
people account for one third of people with dementia 1, while 64% of people receiving 
Medicare in US nursing homes have dementia 2. These individuals have complex needs due 
to the unique set of cognitive and functional impairments that characterise moderate to severe 
dementia. These are further compounded by neuropsychiatric symptoms, medical 
comorbidity and loss of communication ability 3. Neuropsychiatric symptoms affect 90% of 
people with dementia at some point, and are particularly impactful with individuals requiring 
additional support to intiate and engage with activities 4. Apathy is possibly the most frequent 
neuropsychiatric symptom, but is relatively underresearched.  
 Apathy is not merely a symptom, but a multidimensional syndrome affecting 
cognitive, emotional, and behavioural domains 5,6, and it causes clinically significant 
functional impairment in many people with dementia 7. It is widely prevalent, persistent, and 
therapeutically challenging in people with dementia 8, especially those with moderate to 
severe dementia living in nursing homes 9. A recent systematic review including 28 studies 
reported the mean prevalence of apathy in people with dementia living in nursing homes to 
be 36% (range: 17-82%) 9. Moreover, apathy is associated with high levels of disability, 
faster cognitive and functional decline, weight loss, poor quality of life, high caregivers’ 
burden, poor quality of care, poor rehabilitation, and increased risk of mortality 8,10-13. 
 Systematic research on the management of apathy remain sparse 10,14. 
Acetylcholinesterase inhibitors have level II evidence to support their efficacy 14. In the 
context of an increasing effort to reduce the use of antipsychotic medications in people with 
dementia, available evidence does not support the use of antipsychotics to treat apathy 14-16. 
The literature regarding non-pharmacological treatments for apathy is limited 10, but some 
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preliminary studies indicate the potential of tailored therapeutic mentally stimulating 
activities 17, exercise 18, and social interaction 19.  
 As a part of a cluster randomised controlled trial focussing on people with 
dementia in nursing homes, we examined the impact of a pragmatic intervention to review 
antipsychotic medication. The initial results confirmed that this intervention could achieve a 
significant reduction in antipsychotic use, and that in combination with social interaction 
there was also a significant reduction in mortality. There was however a significant 
worsening in agitation and overall psychiatric symptoms, which was mitigated by social 
interaction and/or exercise 20. This paper examines the frequency of apathy, determines 
whether review of antipsychotic medication led to any worsening of apathy and whether this 
could be mitigated by evidence based non-pharmacological interventions.  
Material and Methods 
Study design: Well-being and health for people with dementia (WHELD) programme 
included this cluster randomised controlled trial with 2X2X2 factorial design with two 
replications 21. As the methodology employed in this study has been reported in detail 
elsewhere 20, it is only briefly presented here. The unit of randomisation was the nursing 
home. Each nursing home (cluster) received a randomly allocated intervention, with most 
homes randomly assigned to more than one of the three interventions, for nine months. The 
study received ethical approval from South-Central Oxford Research Ethics Committee C 
(REC number 11/SC0066). The trial is registered as a clinical trial (ISRCTN number 
40313497), and the protocol is available online at 
http://www.kcl.ac.uk/ioppn/depts/wolfson/about/people/staff/ballardclive.aspx. 
Setting: This study was conducted in 16 nursing homes in UK. Each care home represented a 
cluster that received a randomly allocated intervention for nine months. These nursing homes 
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were identified from those rated ‘adequate’ or better in the care quality commission register 
in 2013, in the Oxfordshire, Buckinghamshire, and London localities. Eight homes were 
selected by probability sampling, and the remaining eight were selected by non-probability 
sampling. We excluded the nursing homes, if less than 60% of their residents had dementia or 
they were in receipt of local authority special support.  
Participants: All residents meeting eligibility criteria were invited to participate. Eligibility 
criteria included the diagnosis of dementia, defined by the Clinical Dementia Rating Scale 
(CDRS) 22 stage 1 or greater, and by Functional Assessment Staging (FAST) 23 stage 4 or 
greater. Consent for nursing home involvement was obtained from the management of the 
homes. If residents lacked capacity to consent, informed consent was obtained with the 
involvement of a nominated or personal consultee who represented the residents’ interests 
and wishes in accordance with the Mental Capacity Act. Study interventions were delivered 
to all residents, with a minimum recruitment target of 12 participants per nursing home. The 
impact of study interventions on antipsychotic use, agitation, depression, neuropsychiatric 
symptoms, and mortality of these participants have already been reported elsewhere 20.  
Interventions: WHELD therapists worked with care staff nominated as dementia champions 
in each home to implement the following four interventions, (i) Person-Centred Care (PCC): 
PCC was implemented using the tools from the Focussed Intervention for Training of Staff 
manual 24, based on evidenced based approaches for improving care in nursing homes, and 
from a review of other best available training manuals with the aim of personalising and 
tailoring care practice in line with individual preferences and needs 25; (ii) Antipsychotic 
review: The WHELD therapists helped  the homes’ dementia champions to develop effective 
processes within the nursing homes to prompt antipsychotic review according to the best 
practice guidelines. Moreover, they worked with the physicians and nursing home staff to 
augment PCC during the antipsychotic withdrawal period. The participants’ primary care 
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physicans or specialist psychiatrists reviewed long-term prescriptions of antipsychotics on the 
basis of the National Institute for Health and Care Excellence (NICE) dementia guidelines 26 
and of the antipsychotic care pathway, developed by the Alzheimer’s Society in partnership 
with the Department of Health 27. These guidelines emphasised careful medical assessment of 
underlying causes of neuropsychiatric symptoms such as pain and factors leading to delirium, 
the use of nonpharmacological interventions as a first-line approach before considering 
pharmacotherapy (unless symptoms were severe or involving immediate risks), regular 
review of antipsychotic prescriptions in people on long-term antipsychotic medications, and 
the recommendation to constrain treatment periods with newly commenced antipsychotics to 
a maximum duration of 12 weeks. A trial discontinuation was recommended as the preferred 
practice for patients who had had antipsychotic prescriptions for more than 3 months, but 
caution was recommended in people with baseline Neuropsychiatric Inventory scores above 
14 on the basis of evidence from a previous randomised controlled trial 28; (iii) Exercise: 
enjoyable positive physical activities were encouraged on the basis of the Seattle protocols 29, 
and exercise elements of the NEST manual 30. Previous and current interests of the 
participants, and their current level of health and fitness were assessed. The aim was for 
participants to be engaged in at least one hour of exercise per week. If they were doing this at 
baseline, the amount of exercise was increased by 20% by the end of the intervention period; 
(iv) Social interaction with pleasant activities: A social interaction intervention manual was 
developed on the basis of three evidence based approaches, the positive events schedule from 
the Seattle protocols 29, the social activities elements of the NEST manual 30, and the social 
interaction intervention, developed by Cohen-Mansfield and colleagues 31. Individualised 
plans for activities and staff-resident interactions were developed using a life history 
appproach and assessment of current interests. The aim was for participants to be engaged in 
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at least one hour of social interaction per week. If this was taking place at baseline, the 
amount of social interaction was increased by 20% by the end of the intervention period.  
Randomisation: All 16 nursing homes received PCC. After constrained complete list 
randomisation, stratified on the three participating sites 32, antipsychotic review, exercise, and 
social interaction were implemented in eight care homes each. The constraint ensured an 
approximately equal distribution of the number of study interventions to each geographic 
location. Eight nursing homes were randomly assigned to antipsychotic review, eight to an 
intervention to increase social interaction, and eight to an exercise intervention. Each possible 
combination of interventions was assigned to two nursing homes exclusively. A trained 
WHELD therapist coordinated each intervention into the eight nursing homes that were 
randomised to receive that intervention. In each nursing home, a minimum of two lead care 
staff members were trained to implement that intervention.  
Outcome measures: Apathy was one of the outcomes of the WHELD trial, and it was was 
assessed by the Neuropsychiatric Inventory Nursing Home version (NPI-NH) 33. G domain of 
NPI-NH evaluated apathy over the four weeks prior to assessment using a screening question, 
and seven sub-questions. When apathy was identified, NPI-NH documented its frequency in 
four-point scale, and its severity in a three-point scale. An apathy domain score was 
calculated by multiplying frequency and severity scores. This score was zero, when apathy 
was absent, and it ranged from one to 12, when apathy was present. Depression, anxiety, and 
agitation of the participants were evaluated using the Cornell Scale for Depression in 
Dementia (CSDD) 34, Rating Anxiety In Dementia (RAID) 35, and Cohen-Mansfield 
Agitation Inventory (CMAI) 36, respectively. Needs and quality of life of the participants 
were systematically assessed using the Camberwell Assessment of Need for the Elderly 
(CANE) 37, and assessment of quality of life for people with dementia (DEMQoL) 38, 
respectively. Assessments were carried out at baseline before randomisation, and after the 
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completion of nine month-long interventions by research assistants, blind to intervention 
allocation. The factorial design with all nursing homes receiving at least one intervention 
helped in maintaining the blinding.  
Statistical analyses: We analysed the data from WHELD cluster randomised controlled trial 
using data pertaining to apathy from the same randomised participants reported previously 
20,21. Participants’ characteristics, their clinical profile, and apathy scores were initially 
analysed by descriptive statistics. Missing values of items within the study questionnaires 
were replaced with the mean scores of the remaining items in the questionnaires as long as 
the number of missing items did not exceed 20% of the total number of items in the 
questionnaires. Prevalence of apathy at baseline was compared with that after the nine 
months intervention period using the McNemar’s test. Statistical significance of difference 
between the NPI-NH G domain apathy scores at the two time points was analysed by the 
Wilcoxon signed-rank test. Appropriate statistical tests of significance were employed to 
analyse the observed differences between the participants with and without apathy. 
Correlations between apathy scores and CDR, FAST, CSDD, RAID, CMAI, CANE, as well 
as DEMQoL scores were assessed using Spearman's rank-order correlation with Bonferroni 
corrections at baseline and after the nine months intervention period.  
 The impact of antipsychotic review on apathy in people with dementia living in 
nursing homes was analysed by multilevel mixed effects linear regression models with 
maximum likelihood estimation method. Further analyses were undertaken to determine the 
impact of combining antipsychotic review with social interaction or exercise. Individual 
participants were nested within a higher level, the nursing homes. Differences between the 
NPI-NH apathy scores at the two time points was the outcome variable. Study interventions 
were the independent variables. Age and gender of the participants, as well as FAST and 
CSDD scores at baseline were included as covariates. Although FAST stages were naturally 
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ordered, they were modelled as linear effects to increase the power of the statistical analyses. 
Participants that did not receive any interventions except the PCC intervention formed the 
reference group. Clustered robust standard errors for the estimated regression coefficients 
were calculated with the nursing homes as the clustering variable. Only the participants that 
completed the nine months intervention period were included in these analyses. We repeated 
these analyses by including only the participants with moderately severe and severe 
dementia, defined by FAST stages six and seven at baseline. All analyses were performed 
using the statistical software STATA 13.1 (StataCorp, Texas, USA). 
 
Results 
Participant characteristics: 273 people with dementia living in 16 nursing homes were 
assessed for apathy at baseline, and 191 (70.0%) of them completed the nine months 
intervention period. Figure 1 presents the participant flow diagram of the WHELD RCT. 
Presence of apathy at baseline was not significantly associated with death (χ2=0.10; df=1; 
p=0.75), but was significantly associated with withdrawal from the study (χ2=8.04; df=1; 
p=0.005). Table 1 presents the baseline characteristics of participants with and without 
apathy. 73.6% (95% CI 68.0-78.5%) of the participants were women, and 89.0% (95% CI 
84.7-92.2%) of them were Caucasian. Mean age of the participants was 85.3 (95% CI 84.4-
86.1) years at baseline. Age of the participants did not differ significantly between the 16 
nursing homes (Kruskal-Wallis χ2=16.18; df=15; p=0.37). Table 2 presents baseline 
characteristics of the participants, who received and did not receive antipsychotic review, 
social interaction, and exercise. 
Prevalence and correlates of apathy: 120 participants (44.0%; 95% CI 38.1-49.9%) had 
apathy at baseline. Mean NPI-NH G domain apathy scores at baseline was 2.32 (95% CI 
1.91-2.73). Participants with and without apathy at baseline did not differ significantly in 
10 
 
gender, age, ethnicity, number of years lived in the nursing homes, or the current prescription 
of antipsychotic medications. Table 3 presents the correlations between NPI-NH apathy 
scores, and severity of dementia, neuropsychiatric symptoms, depressive symptoms, anxiety 
symptoms, agitation, quality of life, and the needs of the people with dementia at baseline and 
after the nine months intervention period. Severity of apathy at baseline showed significant 
positive correlations with severity of dementia, overall neuropsychiatric symptoms, 
depression, agitation, and overall needs after Bonferroni corrections (p<0.001). 85 
participants (44.5%; 95% CI 37.5-51.7%) had apathy after the nine months intervention 
period. Mean NPI-NH apathy scores at follow-up was 2.60 (95% CI 2.08-3.13). Categorical 
presence of apathy among the participants did not change significantly between the two time 
points (McNemar’s χ2=0.47; df=1; p=0.49), and the numerical increase in the NPI-NH apathy 
scores at follow-up was not statistically significant (Wilcoxon matched-pairs signed-rank test 
z=1.48; p=0.14). However, increased apathy correlated with increased severity of dementia 
(rs=0.15; p=0.04), and with increased needs of the people with dementia (rs=0.20; p=0.007) 
between the two time points. Moreover, it showed significant negative correlation with the 
changes in the quality of life for the people with dementia during the study (rs=-0.15; 
p=0.04).  
Impact of antipsychotic review on apathy: Antipsychotic review alone significantly 
increased apathy (β=5.37; SE=0.91; p<0.001), (Cohen’s d=-0.97). However, antipsychotic 
review in combination with either social interaction (Cohen’s d=0.49) or exercise (Cohen’s 
d=0.20) reduced apathy, and this reduction was statistically significant, after adjusting for the 
effects of age, gender, baseline dementia severity, and baseline depressive symptoms (Table 
4). Further analyses including only the participants with moderately severe and severe 
dementia confirmed that antipsychotic review (β=6.75; SE=1.31; p<0.001), when delivered 
alone, significantly increased the severity of apathy, and that antipsychotic review in 
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combination with either social interaction (β=-6.59; SE=1.58; p<0.001) or exercise (β= -
10.51; SE=1.32; p<0.001) significantly reduced the severity of apathy, after adjusting for the 
effects of age, gender, baseline dementia severity, and baseline depressive symptoms. 
Moreover, analyses including only the participants, who did not receive any antipsychotics at 
the baseline, confirmed that antipsychotic review (β=4.24; SE=1.55; p=0.006), when 
delivered alone, significantly increased the severity of apathy, and that antipsychotic review 
in combination with either social interaction (β=-4.10; SE=1.86; p=0.03) or exercise (β= -
8.93; SE=1.97; p<0.001) significantly reduced the severity of apathy, after adjusting for the 
effects of age, gender, baseline dementia severity, and baseline depressive symptoms. 
Apathy and depression: Mean CSDD score of the people with dementia was 5.00 (95% CI 
4.46-5.54) at baseline, and 4.59 (95% CI 3.93-5.25) after the nine month intervention period 
(Wilcoxon matched-pairs signed-rank test z=0.07; p=0.94). Correlation between the changes 
in the severity of apathy and the changes in the severity of depressive symptoms during the 
study was not statistically significant (rs=0.08; p=0.30). Changes in the severity of apathy 
between the two time points did not significantly change the severity of depressive symptoms 
(β=0.10; SE=0.08; p=0.22), after adjusting for the effects of age, gender, and baseline 
dementia severity of the participants. 
Discussion 
 This study has confirmed that apathy is common in people with dementia living 
in nursing homes, and identified significant correlations with the severity of dementia and 
other neuropsychiatric symptoms. Worsening of apathy over nine months of follow-up was 
significantly associated with increased overall needs, and with worsening quality of life. 
Importantly, antipsychotic review was associated with worsening apathy. However, when 
antipsychotic review was undertaken in combination with social interaction or personalised 
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exercise, this not only mitigated the apparent detrimental impact but led to significant 
improvement. Changes in the severity of apathy were not significantly correlated with the 
changes in the severity of depressive symptoms, providing further evidence that apathy is an 
independent neuropsychiatric syndrome. Correlations of apathy with CMAI, CSDD, and 
RAID scores were not statistically significant after follow-up. This finding may be explained 
either by smaller numbers at the follow-up or by distinct progressive courses of these 
neuropsychiatric symptoms associated with dementia. 
 The detrimental impact of antipsychotic review on apathy is an important point, 
and consistent with detrimental effects on other neuropsychiatric symptoms (26). 
Antipsychotic review was conducted by following guidance on managing neuropsychiatric 
symptoms that was published during the UK government drive to reduce antipsychotic use in 
the last five years, which has led to substantial reductions. This guidance has led to a shift in 
the landscape of antipsychotic prescribing in the UK whereby people now receiving 
antipsychotic medications have more severe neuropsychiatric symptoms than the previous 
cohorts. The additional evidence from this study that discontinuation of antipsychotics also 
impacts upon apathy adds weight to the need for review of the existing guidelines including 
greater emphasis on the use of evidence-based non-pharmacological interventions in 
conjunction with antipsychotic review. 
 Prevalence of apathy among the participants of this study was similar to the 
mean prevalence of apathy, reported by a recent systematic review 9, in people with dementia 
living in nursing homes. Our findings corroborate previous studies that have reported the 
importance of apathy in increasing needs and worsening quality of life of people with 
dementia 12,19,39. Categorical presence of apathy among the participants did not change 
significantly between the two time points of this study. Moreover, apathy and depressive 
symptoms differed on their courses and their responses to study interventions 20. Such 
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persistence, prognostic significance, and distinctness from depression argue for the 
nosological validity of apathy as a separate neuropsychiatric syndrome. Recognising apathy 
as a separate syndrome and validating proposed diagnostic criteria for apathy 40 will reduce 
under-recognition 41 and should lead to improvement of its management in people with 
dementia. 
 Strengths of this study include a robust design, with a relatively large sample 
size and long follow-up period, the inclusion of people with moderately severe and severe 
dementia and high retention of surviving participants. The interventions followed best 
practice guidelines for antipsychotic review and evidence based approaches for SI and 
analyses explored the effects of combined interventions. Selection bias was minimised by 
randomisation, and by including all eligible consenting residents in the nursing homes. 
Observer bias was reduced by blinding the research assistants, who assessed outcomes, to 
intervention allocation. Contamination was avoided by the cluster RCT design. It is important 
to acknowledge some limitations of the study. Definition of apathy is still evolving 42, and 
standardised assessment guidelines to diagnose apathy are lacking 6,10. Reduction of apathy 
was not the primary outcome of the WHELD trial, and the randomisation did not stratify the 
participants on the presence of apathy 20. Moreover, our analyses considered all subtypes of 
dementia as one category, but the effects of studied interventions on apathy in people with 
various subtypes of dementia may differ. Furthermore, the pragmatic nature of this RCT 
allowed including people with multiple concurrent medications.  
 Weak evidence base for available non-pharmacological interventions for apathy 
in people with dementia may be attributed to poor quality of research rather than lack of 
efficacy of these interventions 10. Apathy in people with dementia, including those with 
severe dementia living in nursing homes, can be approached with therapeutic optimism. 
Significant reduction in the severity of apathy can be achieved, if judicial review of 
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pharmacological interventions is combined with appropriate non-pharmacological 
interventions. Standardising assessment guidelines and diagnostic criteria for apathy is 
essential to evaluate the efficacy of potential interventions, and to investigate the 
neurobiological mechanisms underlying apathy. More large and rigorous RCTs investigating 
the efficacy of combined pharmacological and non-pharmacological interventions to reduce 
apathy in people with dementia are needed. 
 
Conclusion 
 This study confirms the high prevalence and impact of apathy in people with 
dementia living in nursing homes. Of particular note, review of antipsychotic medication as a 
single therapeutic intervention led to a significant worsening in apathy. However, 
undertaking antipsychotic review in conjunction with the implementation of evidence based 
non-pharmacological interventions led to significant improvements. The results emphasise 
the importance of amending current best practice guidelines to emphasise the importance of 
implementing non-pharmacological interventions as part of the process of reviewing and 
discontinuing antipsychotic medication in people with dementia.  
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Table 1: Baseline characteristics of participants with (n=120) and without apathy (n=153)  
 
Characteristic 
Without apathy 
n (%) /  
Mean (SD) 
With apathy a 
n (%) /  
Mean (SD) 
 
χ2 / t b/ 
z c 
 
p 
Female gender 113 (73.9) 88 (73.3) 0.01 0.92 
Age in years 85.7 (6.8) 84.7 (7.0) 1.13 c 0.26 
Ethnicity: Caucasian 136 (88.9) 107 (89.2) 0.01 0.94 
Years lived in nursing homes 2.1 (2.0) 2.5 (2.2) -1.21 c 0.22 
CDR Mild (0.5-1) 28 (18.3) 5 (4.2)  
25.34 
 
< 0.001 Moderate (2) 72 (47.1) 40 (33.3) 
Severe (3) 53 (34.6) 75 (62.5) 
FAST Mild  25 (16.3) 5 (4.2)  
15.35 
 
0.002 Moderate 12 (7.8) 4 (3.3) 
Moderately severe 94 (61.4) 82 (68.3) 
Severe 22 (14.4) 29 (24.2) 
NPI-NH total score d 9.7 (11.4) 25.5 (18.5) -8.72 c < 0.001 
CMAI total score 43.7 (15.0) 53.8 (17.5) -5.07 c < 0.001 
CSDD total score 4.2 (4.2) 6.1 (4.6) -4.03 c < 0.001 
RAID total score 4.5 (4.4) 6.0 (5.6) -2.24 c 0.03 
CANE total number of needs 14.4 (2.4) 16.1 (2.8) -5.38 b < 0.001 
DEMQoL total score 105.4 (12.2) 102.6 (12.6) 2.13 c 0.03 
Currently on antipsychotics 22 (14.4) 26 (21.7) 2.46 0.12 
a Neuropsychiatric inventory- nursing home version (NPI-NH) G domain, apathy, score above 0; b 
Two-sample t test with equal variances; c Two-sample Wilcoxon rank-sum test z value; CDR: Clinical 
Dementia Rating; FAST: Functional Assessment Staging Test; d Total score of all 12 domains of NPI-
NH; CMAI: Cohen-Mansfield agitation inventory; CSDD: Cornell Scale for Depression in Dementia; 
RAID: Rating anxiety in dementia; CANE: Camberwell assessment of need for the elderly; 
DEMQoL: Assessment (Proxy) of quality of life for people with dementia  
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Table 2: Baseline characteristics of participants, who received and did not receive antipsychotic review, social interventions, and exercise 
 
Characteristic 
AR (n=143) 
n (%) /  
Mean (SD) 
No AR (n=130) 
n (%) /  
Mean (SD) 
SI (n=138) 
n (%) /  
Mean (SD) 
No SI (n=135) 
n (%) /  
Mean (SD) 
EX (n=136) 
n (%) /  
Mean (SD) 
No EX (n=137) 
n (%) /  
Mean (SD) 
Female gender 107 (74.8) 94 (72.3) 94 (68.1) 107 (79.3) 92 (67.7) 109 (80.0) 
Age in years 85.4 (6.9) 85.1 (7.0) 84.7 (7.3) 85.8 (6.4) 85.3 (6.5) 85.2 (7.3) 
Ethnicity: Caucasian 129 (90.2) 114 (87.7) 118 (85.5) 125 (92.6) 118 (86.8) 125 (91.2) 
Years lived in nursing homes 2.5 (2.1) 2.1 (2.1) 2.4 (2.4) 2.2 (1.8) 2.5 (2.3) 2.0 (1.9) 
CDR Mild (0.5-1) 19 (13.3) 14 (10.8) 13 (9.4) 20 (14.8) 17 (12.5) 16 (11.7) 
Moderate (2) 59 (41.3) 53 (40.8) 49 (35.5) 63 (46.7) 51 (37.5) 61 (44.5) 
Severe (3) 65 (45.5) 63 (48.5) 76 (55.1) 52 (38.5) 68 (50.0) 60 (43.8) 
FAST Mild  19 (13.3) 11 (8.5) 7 (5.1) 23 (17.0) 13 (9.6) 17 (12.4) 
Moderate 8 (5.6) 8 (6.2) 7 (5.1) 9 (6.7) 6 (4.4) 10 (7.3) 
Moderately severe 92 (64.3) 84 (64.6) 91 (65.9) 85 (63.0) 89 (65.4) 87 (63.5) 
Severe 24 (16.8) 27 (20.8) 33 (23.9) 18 (13.3) 28 (20.6) 23 (16.8) 
NPI-NH total score d 15.3 (16.3) 18.1 (17.4) 17.6 (17.2) 15.6 (16.4) 14.7 (16.5) 18.5 (17.0) 
18 
 
NPI-NH apathy score a 2.0 (3.2) 2.7 (3.7) 2.2 (3.4) 2.4 (3.5) 2.1 (3.3) 2.6 (3.5) 
CMAI total score 47.2 (15.8) 48.9 (18.0) 49.1 (16.6) 46.9 (17.1) 47.1 (15.9) 49.0 (17.8) 
CSDD total score 4.4 (4.0) 5.6 (4.8) 5.3 (4.2) 4.7 (4.7) 4.7 (4.2) 5.3 (4.7) 
RAID total score 4.8 (4.4) 5.6 (5.6) 5.3 (4.8) 5.1 (5.2) 5.2 (5.0) 5.2 (5.1) 
CANE total number of needs 15.0 (2.6) 15.3 (2.8) 15.6 (2.9) 14.7 (2.5) 15.3 (2.5) 15.0 (2.9) 
DEMQoL total score 105.9 (9.4) 102.2 (15.0) 106.0 (11.8) 102.4 (12.9) 105.0 (12.1) 103.3 (12.8) 
Currently on antipsychotics 25 (17.5) 23 (17.7) 13 (9.4) 35 (25.9) 29 (21.3) 19 (13.9) 
 
a Neuropsychiatric inventory- nursing home version (NPI-NH) G domain apathy scores; CDR: Clinical Dementia Rating; FAST: Functional Assessment 
Staging Test; d Total score of all 12 domains of NPI-NH; CMAI: Cohen-Mansfield agitation inventory; CSDD: Cornell Scale for Depression in Dementia; 
RAID: Rating anxiety in dementia; CANE: Camberwell assessment of need for the elderly; DEMQoL: Assessment (Proxy) of quality of life for people with 
dementia  
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Table 3: Clinical correlates of apathy a among people with dementia living in nursing homes  
Clinical variable At baseline b 
(n=273) 
p c At follow-up d 
(n=191) 
p c 
CDR score 0.34 < 0.001 0.37 < 0.001 
FAST score 0.26 < 0.001 0.29 0.002 
NPI-NH total score e 0.58 < 0.001 0.46 < 0.001 
CMAI total score 0.31 < 0.001 0.16 1.00 
CSDD total score 0.26 < 0.001 0.13 1.00 
RAID total score 0.13 1.00 0.03 1.00 
CANE total score 0.33 < 0.001 0.16 1.00 
DEMQoL total score -0.15 0.70 -0.08 1.00 
 
a Neuropsychiatric inventory- nursing home version (NPI-NH) G domain, apathy, scores ranging from 
0 to 12; b Spearman correlation coefficients at baseline; c p values after Bonferroni correction for 
multiple testing; d Spearman correlation coefficients after 9 months follow-up; CDR: Clinical 
Dementia Rating; FAST: Functional Assessment Staging Test; d Total score of all 12 domains of NPI-
NH; CMAI: Cohen-Mansfield agitation inventory; CSDD: Cornell Scale for Depression in Dementia; 
RAID: Rating anxiety in dementia; CANE: Camberwell Assessment of Need for the Elderly; 
DEMQoL: Assessment (Proxy) of quality of life for people with dementia  
 
 
 
 
 
 
 
 
 
 
 
20 
 
Table 4: Changes in the severity of apathy a following antipsychotic review and non-pharmacological interventions in people with dementia 
living in nursing homes  
Intervention AR alone (n=43) AR and SI (n=31) AR and EX (n=27) 
Baseline apathy score (Mean (SD)) 1.37 (2.02) 1.77 (3.27) 2.74 (3.89) 
Antipsychotic use at baseline (n (%)) 6 (13.95) 1 (3.23) 9 (33.33) 
Follow-up apathy score (Mean (SD)) 4.13 (4.13) 2.28 (3.58) 1.05 (2.16) 
Changes in apathy from baseline to follow-up (Mean (SD)) 2.75 (4.09) 0.36 (4.10) -1.05 (4.13) 
Discontinuing antipsychotics (n (%)) b 5 (11.63) 0 (0.00) 2 (7.41) 
Unadjusted difference in apathy between the groups (Mean (SD)) c 5.58 (4.31) 3.19 (4.35) 1.78 (4.39) 
Adjusted difference in apathy between the groups (β) d 5.37 -5.84 -7.54 
95% CI of β e 3.58 – 7.15 -8.10 – -3.58 -9.35 – -5.72 
z  5.90 -5.06 -8.14 
p value < 0.001 < 0.001 < 0.001 
 
a Neuropsychiatric inventory- nursing home version (NPI-NH) G domain, apathy, scores; b Number of people, who were on antipsychotics at baseline but not 
on antipsychotics at the follow-up; c Unadjusted differences among the changes in the severity of apathy from baseline to follow-up between the intervention 
arm and the participants that did not receive any interventions except the person-centred care (PCC) (n=33); d Regression coefficients, estimated by multilevel 
mixed effects linear regression model with the changes in the severity of apathy as the dependent variable, nursing homes as the clustering variable, 
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various interventions as the independent variables, and age and gender of the participants, as well as Functional Assessment Staging Test and 
Cornell Scale for Depression in Dementia scores at baseline as covariates. Participants that did not receive any interventions except PCC formed the reference 
group (n=33); e Clustered robust standard errors were calculated with 
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